Approche pratique des anomalies des enzymes hépatiques chez les patients atteints d’une maladie inflammatoire de l’intestin
Résumé
Les maladies inflammatoires de l’intestin (MII) sont des maladies inflammatoires chroniques qui peuvent toucher d’autres organes que le tractus gastro-intestinal. Les manifestations extra-intestinales (MEI) des MII sont fréquentes et peuvent survenir à n’importe quel stade de la maladie.1 Même si les MEI touchent le plus souvent le système musculo-squelettique, jusqu’à 35 % des personnes atteintes de MII présentent une atteinte hépatobiliaire à un moment ou à un autre de l’évolution de leur maladie, souvent indépendamment de l’activité de la maladie.2 On observe des maladies hépatobiliaires chroniques chez 5 % des patients atteints de MII.3 Ces maladies se manifestent par des symptômes évocateurs, des bilans hépatiques anormaux ou des anomalies radiologiques. Cette revue présente un aperçu complet et une approche des enzymes hépatiques anormales chez les personnes atteintes de MII.
Références
Rogler G, Singh A, Kavanaugh A, Rubin DT. Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management. Gastroenterology. 2021;161(4):1118-32. doi: 10.1053/j.gastro.2021.07.042
Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(8):1982-92. doi: 10.1097/MIB.0000000000000392
Mendes FD, Levy C, Enders FB, Loftus EV Jr, Angulo P, Lindor KD. Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol. 2007;102(2):344-50. doi: 10.1111/j.1572-0241.2006.00947.x
Kalas MA, Chavez L, Leon M, Taweesedt PT, Surani S. Abnormal liver enzymes: a review for clinicians. World J Hepatol. 2021;13(11):1688-98. doi: 10.4254/wjh.v13.i11.1688
Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenerol. 2017;112(1):18-35. doi: 10.1038/ajg.2016.517.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis–2021 update. J Hepatol. 2021;75(3):659-89. doi: 10.1016/j.jhep.2021.05.025
Cheng YW, McLean R, Sewell JL, Huang CY, Khalili M. Inflammatory bowel disease type influences development of elevated liver enzymes. JGH Open. 2022;6(12):846-53. doi: 10.1002/jgh3.12831
Cappello M, Randazzo C, Bravatà I, Licata A, Peralta S, Craxì A, et al. Liver function test abnormalities in patients with inflammatory bowel diseases: a hospital-based survey. Clin Med Insights Gastroenterol. 2014;7:25-31. doi: 10.4137/CGast.S13125.
Lin A, Roth H, Anyane-Yeboa A, Rubin DT, Paul S. Prevalence of nonalcoholic fatty liver disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2020;27(6):947-55. doi: 10.1093/ibd/izaa189
Bessissow T, Le NH, Rollet K, Afif W, Bitton A, Sebastiani G. Incidence and predictors of nonalcoholic fatty liver disease by serum biomarkers in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(8):1937-44. doi: 10.1097/MIB.0000000000000832
Mancina RM, Spagnuolo R, Milano M, Brogneri S, Morrone A, Cosco C, et al. PNPLA3 148M carriers with inflammatory bowel diseases have higher susceptibility to hepatic steatosis and higher liver enzymes. Inflamm Bowel Dis. 2016;22(1):134-40. doi: 10.1097/MIB.0000000000000569
Newsome PN, Cramb R, Davison SM, Dillon JF, Foulerton M, Godfrey EM, et al. Guidelines on the management of abnormal liver blood tests. Gut. 2018;67(1):6-19. doi: 10.1136/gutjnl-2017-314924
Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-835. doi: 10.1097/HEP.0000000000000323
Saroli Palumbo C, Restellini S, Chao C-Y, Aruljothy A, Lemieux C, Wild G, et al. Screening for nonalcoholic fatty liver disease in inflammatory bowel diseases: a cohort study using transient elastography. Inflamm Bowel Dis. 2018;25(1):124-33. doi: 10.1093/ibd/izy200
Barberio B, Massimi D, Cazzagon N, Zingone F, Ford AC, Savarino EV. Prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease: a systematic review and meta-analysis. Gastroenterology. 2021;161(6):1865-77. doi: 10.1053/j.gastro.2021.08.032
Lunder AK, Hov JR, Borthne A, Gleditsch J, Johannesen G, Tveit K, et al. Prevalence of sclerosing cholangitis detected by magnetic resonance cholangiography in patients with long-term inflammatory bowel disease. Gastroenterology. 2016;151(4):660-9. e4. doi: 10.1053/j.gastro.2016.06.021
Saich R, Chapman R. Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J Gastroenterol. 2008;14(3):331-7. doi: 10.3748/wjg.14.331
Bowlus CL, Arrivé L, Bergquist A, Deneau M, Forman L, Ilyas SI, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2023;77(2):659-702. doi: 10.1002/hep.32771
Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002;56(1):48-54. doi: 10.1067/mge.2002.125367
Janse M, Lamberts LE, Franke L, Raychaudhuri S, Ellinghaus E, Muri Boberg K, et al. Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9. Hepatology. 2011;53(6):1977-85. doi: 10.1002/hep.24307
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on sclerosing cholangitis. J Hepatol. 2022;77(3):761-806. doi: 10.1016/j.jhep.2022.05.011
DeFilippis EM, Kumar S. Clinical presentation and outcomes of autoimmune hepatitis in inflammatory bowel disease. Dig Dis Sci. 2015;60(10):2873-80. doi: 10.1007/s10620-015-3699-4.
Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology. 2020;72(2):671-722. doi: 10.1002/hep.31065
Hennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48(1):169-76. doi: 10.1002/hep.22322.
Colina F, Molero A, Casís B, Martínez-Montiel P. Infliximab-related hepatitis: a case study and literature review. Dig Dis Sci. 2013;58:3362-7. doi: 10.1007/s10620-013-2698-6.
Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet. 2010;375(9715):657-63. doi: 10.1016/S0140-6736(09)61963-2
Gizard E, Ford AC, Bronowicki J-P, Peyrin-Biroulet L. Systematic review: the epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2014;40(1):3-15. doi: 10.1111/apt.12794
Naymagon L, Tremblay D, Zubizarreta N, Moshier E, Naymagon S, Mascarenhas J, et al. The natural history, treatments, and outcomes of portal vein thrombosis in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2021;27(2):215-23. doi: 10.1093/ibd/izaa053
Benmassaoud A, AlRubaiy L, Yu D, Chowdary P, Sekhar M, Parikh P, et al. A stepwise thrombolysis regimen in the management of acute portal vein thrombosis in patients with evidence of intestinal ischaemia. Aliment Pharmacol Ther. 2019;50(9):1049-58. doi: 10.1111/apt.15479
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol. 2016;64(1):179-202.
Baig MM, Irfan SA, Sumbal A, Sumbal R, Kumar S, Ahmad J, et al. Prevalence of gallstones in ulcerative colitis and crohn’s disease: a systematic review and meta-analysis. Cureus. 2022;14(6):e26121. doi: 10.7759/cureus.26121
Restellini S, Chazouillères O, Frossard J-L. Hepatic manifestations of inflammatory bowel diseases. Liver Int. 2017;37(4):475-89. doi: 10.1111/liv.13265
Zhang FM, Xu CF, Shan GD, Chen HT, Xu GQ. Is gallstone disease associated with inflammatory bowel diseases? A meta‐analysis. J Dig Dis. 2015 Nov;16(11):634-41. doi: 10.1111/1751-2980
Coffin CS, Fung SK, Alvarez F, Cooper CL, Doucette KE, Fournier C, et al. Management of hepatitis B virus infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada. Can Liver J. 2018;1(4):156-217. doi: 10.3138/canlivj.2018-0008
Núñez F P, Quera R, Bay C, Castro F, Mezzano G. Drug-induced liver injury used in the treatment of inflammatory bowel disease. J Crohns Colitis. 2022;16(7):1168-76. doi: 10.1093/ecco-jcc/jjac013
Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):221-44. e3. doi: 10.1053/j.gastro.2014.10.038.
Rahier J-F, Ben-Horin S, Chowers Y, Conlon C, De Munter P, D'Haens G, et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2009;3(2):47-91. doi: 10.1016/j.crohns.2009.02.010
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: drug-induced liver injury. J Hepatol. 2019;70(6):1222-61. doi: 10.1016/j.jhep.2019.02.014
Hoofnagle JH. LiverTox: a website on drug-induced liver injury. In: Kaplowitz N, DeLeve LD, editors. Drug-induced liver disease 3rd ed. Elsevier; 2013. p. 725-32.
Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2015;17(1):14. doi: 10.3390/ijms17010014
Chaparro M, Ordás I, Cabré E, Garcia-Sanchez V, Bastida G, Peñalva M, et al. Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients. Inflamm Bowel Dis. 2013;19(7):1404-10. doi: 10.1097/MIB.0b013e318281f28f.
Tominaga K, Sugaya T, Tanaka T, Kanazawa M, Iijima M, Irisawa A. Thiopurines: recent topics and their role in the treatment of inflammatory bowel diseases. Front Pharmacol. 2021;11:582291. doi: 10.3389/fphar.2020.582291
Gisbert JP, González-Lama Y, Maté J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol. 2007;102(7):1518-27. doi: 10.1111/j.1572-0241.2007.01187.x
Benmassaoud A, Xie X, AlYafi M, Theoret Y, Bitton A, Afif W, et al. Thiopurines in the management of Crohn's disease: safety and efficacy profile in patients with normal TPMT activity-a retrospective study. Can J Gastroenterol Hepatol. 2016;2016:1034834. doi: 10.1155/2016/1034834
Feagan BG, Chande N, MacDonald JK. Are there any differences in the efficacy and safety of different formulations of Oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? evidence from cochrane reviews. Inflamm bowel dis. 2013;19(9):2031-40. doi: 10.1097/MIB.0b013e3182920108
Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, et al. ECCO Guidelines on Therapeutics in Crohn's Disease: medical treatment. J Crohns Colitis. 2020;14(1):4-22. doi: 10.1093/ecco-jcc/jjz180
Saibeni S, Bollani S, Losco A, Michielan A, Sostegni R, Devani M, et al. The use of methotrexate for treatment of inflammatory bowel disease in clinical practice. Dig Liver Dis. 2012;44(2):123-7. doi: 10.1016/j.dld.2011.09.015
De Marco D, Bessissow T, Marcus V, Benmassaoud A. Vedolizumab-associated hypereosinophilia and hepatoxicity. ACG Case Rep J. 2022;9(11):e00905. doi: 10.14309/crj.0000000000000905
D’Amico F, Parigi TL, Fiorino G, Peyrin-Biroulet L, Danese S. Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. Therap Adv Gastroenterol. 2019;12:1756284819848631. doi: 10.1177/1756284819848631
Publié
Comment citer
Numéro
Rubrique
Licence
© Canadian IBD Today 2023
Cette œuvre est sous licence Creative Commons Attribution - Pas d'Utilisation Commerciale - Pas de Modification 4.0 International.
